Relationship of Serum Chemerin Concentrations with Coronary Slow Flow: A Pathophysiological and Clinical Analysis.

IF 0.5 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Kardiologiya Pub Date : 2025-06-02 DOI:10.18087/cardio.2025.5.n2888

Aliye Kuyumcu, Mevlüt Serdar Kuyumcu

{"title":"Relationship of Serum Chemerin Concentrations with Coronary Slow Flow: A Pathophysiological and Clinical Analysis.","authors":"Aliye Kuyumcu, Mevlüt Serdar Kuyumcu","doi":"10.18087/cardio.2025.5.n2888","DOIUrl":null,"url":null,"abstract":"Aim: Coronary slow flow (CSF) is a condition characterized by below normal blood flow in coronary arteries without significant coronary stenosis. Its pathophysiology is unclear but may involve inflammation, endothelial dysfunction, and microvascular impairment. Chemerin, an inflammation-related adipokine, has been proposed as a potential biomarker in CSF. This study examines the relationship between serum chemerin concentrations and CSF.Material and methods: A total of 100 patients who underwent coronary angiography were classified into CSF (n=50) and normal coronary flow (NCF, n=50) groups. Coronary flow rates were assessed using the Thrombolysis in Myocardial Infarction Frame Count (TFC) method. Serum chemerin concentrations were measured by ELISA. Logistic regression, correlation, and ROC analyses were performed to identify predictors of CSF and to evaluate diagnostic performance.Results: Chemerin concentrations were significantly higher in the CSF group (p<0.001). Logistic regression identified chemerin as an independent CSF predictor (OR=1.097; 95 % CI: 1.022-1.177; p=0.005). Chemerin concentrations correlated positively with TFC (r=0.713, p<0.001). A chemerin cutoff value of 124.5 ng / ml provided 88 % sensitivity and 80 % specificity for CSF diagnosis.Conclusion: Elevated serum chemerin is associated with CSF, suggesting its role in the pathogenesis of CSF and its potential as a diagnostic biomarker. Further research is needed to explore chemerin-targeted therapies in patients with CSF.","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 5","pages":"21-27"},"PeriodicalIF":0.5000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kardiologiya","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18087/cardio.2025.5.n2888","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Coronary slow flow (CSF) is a condition characterized by below normal blood flow in coronary arteries without significant coronary stenosis. Its pathophysiology is unclear but may involve inflammation, endothelial dysfunction, and microvascular impairment. Chemerin, an inflammation-related adipokine, has been proposed as a potential biomarker in CSF. This study examines the relationship between serum chemerin concentrations and CSF.

Material and methods: A total of 100 patients who underwent coronary angiography were classified into CSF (n=50) and normal coronary flow (NCF, n=50) groups. Coronary flow rates were assessed using the Thrombolysis in Myocardial Infarction Frame Count (TFC) method. Serum chemerin concentrations were measured by ELISA. Logistic regression, correlation, and ROC analyses were performed to identify predictors of CSF and to evaluate diagnostic performance.

Results: Chemerin concentrations were significantly higher in the CSF group (p<0.001). Logistic regression identified chemerin as an independent CSF predictor (OR=1.097; 95 % CI: 1.022-1.177; p=0.005). Chemerin concentrations correlated positively with TFC (r=0.713, p<0.001). A chemerin cutoff value of 124.5 ng / ml provided 88 % sensitivity and 80 % specificity for CSF diagnosis.

Conclusion: Elevated serum chemerin is associated with CSF, suggesting its role in the pathogenesis of CSF and its potential as a diagnostic biomarker. Further research is needed to explore chemerin-targeted therapies in patients with CSF.

查看原文本刊更多论文

血清趋化素浓度与冠状动脉慢血流的关系：病理生理和临床分析。

目的：冠状动脉慢血流（CSF）是一种以冠状动脉血流低于正常水平而无明显冠状动脉狭窄为特征的疾病。其病理生理机制尚不清楚，但可能涉及炎症、内皮功能障碍和微血管损伤。趋化素是一种炎症相关的脂肪因子，已被认为是脑脊液中潜在的生物标志物。本研究探讨血清趋化素浓度与脑脊液的关系。材料与方法：100例行冠状动脉造影的患者分为CSF组（n=50）和冠状动脉正常血流组（NCF组，n=50）。采用心肌梗死框架计数（TFC）方法评估冠状动脉血流速率。ELISA法测定血清趋化素浓度。采用Logistic回归、相关性和ROC分析来确定脑脊液的预测因素并评估诊断效果。结果：脑脊液组趋化素浓度显著升高（p<0.001）。Logistic回归发现趋化素是脑脊液的独立预测因子(OR=1.097；95% ci: 1.022-1.177；p = 0.005)。趋化素浓度与TFC呈正相关（r=0.713, p<0.001）。趋化素的临界值为124.5 ng / ml，诊断脑脊液的敏感性为88%，特异性为80%。结论：血清趋化素升高与脑脊液有关，提示其在脑脊液发病机制中的作用及其作为诊断生物标志物的潜力。需要进一步的研究来探索化学蛋白靶向治疗脑脊液患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Kardiologiya 医学-心血管系统

CiteScore

1.70

自引率

20.00%

发文量

审稿时长

3-8 weeks

期刊介绍： “Kardiologiya” (Cardiology) is a monthly scientific, peer-reviewed journal committed to both basic cardiovascular medicine and practical aspects of cardiology. As the leader in its field, “Kardiologiya” provides original coverage of recent progress in cardiovascular medicine. We publish state-of-the-art articles integrating clinical and research activities in the fields of basic cardiovascular science and clinical cardiology, with a focus on emerging issues in cardiovascular disease. Our target audience spans a diversity of health care professionals and medical researchers working in cardiovascular medicine and related fields. The principal language of the Journal is Russian, an additional language – English (title, authors’ information, abstract, keywords). “Kardiologiya” is a peer-reviewed scientific journal. All articles are reviewed by scientists, who gained high international prestige in cardiovascular science and clinical cardiology. The Journal is currently cited and indexed in major Abstracting & Indexing databases: Web of Science, Medline and Scopus. The Journal''s primary objectives Contribute to raising the professional level of medical researchers, physicians and academic teachers. Present the results of current research and clinical observations, explore the effectiveness of drug and non-drug treatments of heart disease, inform about new diagnostic techniques; discuss current trends and new advancements in clinical cardiology, contribute to continuing medical education, inform readers about results of Russian and international scientific forums; Further improve the general quality of reviewing and editing of manuscripts submitted for publication; Provide the widest possible dissemination of the published articles, among the global scientific community; Extend distribution and indexing of scientific publications in major Abstracting & Indexing databases.